BMY - Here's Why Mirati Therapeutics Jumped 28% in December
Shares of Mirati Therapeutics (NASDAQ: MRTX), a clinical-stage biopharmaceutical company, rose 27.9% in December, according to data from S&P Global Market Intelligence. Investors were revved up by results from an ovarian cancer study involving Mirati's sitravatinib plus tislelizumab, an anti-PD1 antibody from BeiGene (NASDAQ: BGNE).
Most of the attention directed at Mirati Therapeutics is focused on early clinical-stage testing of MRTX849, a KRAS-inhibitor that could end up treating cancer patients with a variety of solid tumors. Sitravatinib's a kinase inhibitor in a late clinical-stage study with Opdivo, a PD1 inhibitor from Bristol-Myers Squibb (NYSE: BMY) that Bristol didn't seem interested in following lackluster mid-stage trial results.
Image source: Getty Images.